Mannose Inhibits the Pentose Phosphate Pathway in Colorectal Cancer and Enhances Sensitivity to 5-Fluorouracil Therapy
Cancers · 13.04.2023 · 15 (8) · 2268
DOI: 10.3390/cancers15082268 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.04.2023. Verfasst von Sadaf Al Hadeethi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107-2020, Lebanon. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon.
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the leading cancers and causes of death in patients. 5-fluorouracil (5-FU) is the therapy of choice for CRC, but it exhibits high toxicity and drug resistance. Tumorigenesis is characterized by a deregulated metabolism, which promotes cancer cell growth and survival. The pentose phosphate pathway (PPP) is required for the synthesis of ribonucleotides and the regulation of reactive oxygen species and is upregulated in CRC. Mannose was recently reported to halt tumor growth and impair the PPP. Mannose inhibitory effects on tumor growth are inversely related to the levels of phosphomannose isomerase (PMI). An in silico analysis showed low PMI levels in human CRC tissues. We, therefore, investigated the effect of mannose alone or in combination with 5-FU in human CRC cell lines with different p53 and 5-FU resistance statuses. Mannose resulted in a dose-dependent inhibition of cell growth and synergized with 5-FU treatment in all tested cancer cell lines. Mannose alone or in combination with 5-FU reduced the total dehydrogenase activity of key PPP enzymes, enhanced oxidative stress, and induced DNA damage in CRC cells. Importantly, single mannose or combination treatments with 5-FU were well tolerated and reduced tumor volumes in a mouse xenograft model. In summary, mannose alone or in combination with 5-FU may represent a novel therapeutic strategy in CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut 1107-2020, Lebanon.
- Department of Pathology and Laboratory Medicine, American University of Beirut, Beirut 1107-2020, Lebanon.
ORCID-Profile: Chirine El-Baba, Berthe Hayar, Riyad El-Khoury, Nadine Darwiche
Förderung
- Medical Practice Plan and the University Research Board of the American University of Beirut in Lebanon
Zitieren
APA
Al Hadeethi, S., El-Baba, C., Araji, K., Hayar, B., Cheikh, I. A., El-Khoury, R., Usta, J., & Darwiche, N. (2023). Mannose Inhibits the Pentose Phosphate Pathway in Colorectal Cancer and Enhances Sensitivity to 5-Fluorouracil Therapy. Cancers, 15(8), 2268. https://doi.org/10.3390/cancers15082268
Vancouver
Al Hadeethi S, El-Baba C, Araji K, Hayar B, Cheikh IA, El-Khoury R, et al. Mannose Inhibits the Pentose Phosphate Pathway in Colorectal Cancer and Enhances Sensitivity to 5-Fluorouracil Therapy. Cancers. 2023;15(8):2268. doi:10.3390/cancers15082268
BibTeX
@article{AlHadeethi2023,
author = {Al Hadeethi, Sadaf and El-Baba, Chirine and Araji, Khaled and Hayar, Berthe and Cheikh, Israa Ahmad and El-Khoury, Riyad and Usta, Julnar and Darwiche, Nadine},
title = {Mannose Inhibits the Pentose Phosphate Pathway in Colorectal Cancer and Enhances Sensitivity to 5-Fluorouracil Therapy},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2268},
doi = {10.3390/cancers15082268}
}
EUVIMED